571 related articles for article (PubMed ID: 22505648)
21. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
[TBL] [Abstract][Full Text] [Related]
22. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
Babbio F; Pistore C; Curti L; Castiglioni I; Kunderfranco P; Brino L; Oudet P; Seiler R; Thalman GN; Roggero E; Sarti M; Pinton S; Mello-Grand M; Chiorino G; Catapano CV; Carbone GM; Bonapace IM
Oncogene; 2012 Nov; 31(46):4878-87. PubMed ID: 22330138
[TBL] [Abstract][Full Text] [Related]
23. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.
Fujii S; Ochiai A
Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425
[TBL] [Abstract][Full Text] [Related]
24. EZH2 methyltransferase and H3K27 methylation in breast cancer.
Yoo KH; Hennighausen L
Int J Biol Sci; 2012; 8(1):59-65. PubMed ID: 22211105
[TBL] [Abstract][Full Text] [Related]
25. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells.
Yang X; Karuturi RK; Sun F; Aau M; Yu K; Shao R; Miller LD; Tan PB; Yu Q
PLoS One; 2009; 4(4):e5011. PubMed ID: 19340297
[TBL] [Abstract][Full Text] [Related]
26. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
[TBL] [Abstract][Full Text] [Related]
27. EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer.
Xu C; Hou Z; Zhan P; Zhao W; Chang C; Zou J; Hu H; Zhang Y; Yao X; Yu L; Yan J
Med Oncol; 2013 Dec; 30(4):713. PubMed ID: 24132606
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
29. Selective EZH2 inhibitor zld1039 alleviates inflammation in cisplatin-induced acute kidney injury partially by enhancing RKIP and suppressing NF-κB p65 pathway.
Wen L; Tao SH; Guo F; Li LZ; Yang HL; Liang Y; Zhang LD; Ma L; Fu P
Acta Pharmacol Sin; 2022 Aug; 43(8):2067-2080. PubMed ID: 34937916
[TBL] [Abstract][Full Text] [Related]
30. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
31. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
32. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.
Shin YJ; Kim JH
PLoS One; 2012; 7(1):e30393. PubMed ID: 22272343
[TBL] [Abstract][Full Text] [Related]
33. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
Pietersen AM; Horlings HM; Hauptmann M; Langerød A; Ajouaou A; Cornelissen-Steijger P; Wessels LF; Jonkers J; van de Vijver MJ; van Lohuizen M
Breast Cancer Res; 2008; 10(6):R109. PubMed ID: 19099573
[TBL] [Abstract][Full Text] [Related]
34. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
Fujii S; Ito K; Ito Y; Ochiai A
J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
[TBL] [Abstract][Full Text] [Related]
35. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
36. Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer.
Taniguchi H; Jacinto FV; Villanueva A; Fernandez AF; Yamamoto H; Carmona FJ; Puertas S; Marquez VE; Shinomura Y; Imai K; Esteller M
Oncogene; 2012 Apr; 31(15):1988-94. PubMed ID: 21892211
[TBL] [Abstract][Full Text] [Related]
37. MiR-543 Promotes Proliferation and Epithelial-Mesenchymal Transition in Prostate Cancer via Targeting RKIP.
Du Y; Liu XH; Zhu HC; Wang L; Ning JZ; Xiao CC
Cell Physiol Biochem; 2017; 41(3):1135-1146. PubMed ID: 28245474
[TBL] [Abstract][Full Text] [Related]
38. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
39. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.
Caretti G; Di Padova M; Micales B; Lyons GE; Sartorelli V
Genes Dev; 2004 Nov; 18(21):2627-38. PubMed ID: 15520282
[TBL] [Abstract][Full Text] [Related]
40. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Koumangoye RB; Andl T; Taubenslag KJ; Zilberman ST; Taylor CJ; Loomans HA; Andl CD
Mol Cancer; 2015 Feb; 14():24. PubMed ID: 25644061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
